AstraZeneca scraps Phase 3 trial of new bispecific in lung cancer
An interim data check revealed that survival goals were likely to be missed by volrustomig, one in a list of new drugs the U.K. company is leaning on to meet an $80 billion sales goal.
AstraZeneca has discontinued a Phase 3 study of one of its cancer drugs. According to Endpoints News, this is the latest in a series of setbacks for the drugmaker.
The study in question was the SAFFRON Phase III trial, which was investigating the combination of Tagrisso (osimertinib) and Orpathys (savolitinib) for patients with EGFR-mutated non-small cell lung cancer.
Investing.com reports that the trial showed statistically significant improvements in progression-free survival and overall survival compared to platinum-based chemotherapy. However, despite these results, AstraZeneca decided to end the study.
Brief written by urgent.news from Endpoints News, Investing.com — 2 reports on this story. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- AstraZeneca touts separate late-stage lung cancer wins with Tagrisso, Enhertu endpoints.news
- AstraZeneca hit by lung cancer drug setback: Pharma giant halts trials of experimental Volrustomig treatment thisismoney.co.uk
- AstraZeneca’s Tagrisso plus Orpathys extends survival in lung cancer investing.com
